Poster presented at the 2025 AACR meeting in Chicago
“Circulating Epstein-Barr Virus microRNAs Associated with Hodgkin Lymphoma Prognosis”
At the 2025 AACR Annual Meeting in Chicago, we presented findings on the potential of Epstein-Barr Virus (EBV) microRNAs as non-invasive biomarkers for Hodgkin Lymphoma (HL) prognosis. This research was conducted through a collaborative effort between Estelle Verburgh (University of Cape Town), Katherine Antel (Medical University of South Carolina), and the Initiative for RNA Medicine at Harvard Medical School. Plasma samples were collected from HL patients in Cape Town, South Africa, a region with a high prevalence of HIV and tuberculosis. From these samples, 42 EBV-encoded microRNAs were profiled using the ID3EAL™ qPCR EBV miRNA panel.
Surprisingly, miRNA expression correlated with disease severity but not with EBV or HIV status. Notable associations included miR-BART17-3p with disease stage and miR-BART2-5p with the International Prognostic Score. Four miRNAs were identified as key indicators of B-symptoms, which correlated with HL progression.
These results highlight the potential of EBV miRNAs as prognostic markers, though larger cohorts are needed for validation. Continued exploration could yield valuable insights into Hodgkin lymphoma biology and therapeutic strategies.
Keywords: AACR, RNA Medicine, Epstein-Barr Virus (EBV), International Prognostic Score, Hodgkin Lymphoma (HL)
Download it here:
Lee EBV Poster AACR 2025 FINAL
Poster Summary:
